ClinicalTrials.gg

Program

darolutamide

Also written as “Darolutamide”, “Darolutamide (Nubeqa, BAY1841788)” and “Darolutamide (BAY1841788, Nubeqa)”.

Its studies are mostly in Prostatic Neoplasms · Prostatic Neoplasms, Castration-Resistant · Bulbo-Spinal Atrophy, X-Linked · Neoplasms · Neoplasm Metastasis, led by 2 companies.

Furthest: phase 4, since Apr 21, 202220 company-led studies, 4 open or runningNext primary completion: Jul 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayer164 open or runningphase 4since Apr 21, 2022Jul 22, 2014Jul 30, 2027phase 3 · NCT05794906
Orion Corporation, Orion Pharma40 open or runningphase 2since Mar 7, 2011Mar 7, 2011none ahead

Also a collaborator on its studies: Keenova Therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 7 studies since Mar 7, 2011.

  1. Jun 6, 2016Phase 3 study in Metastatic Hormone-sensitive Prostate CancerBayer · NCT02799602 · 1,306 enrolled · United States, Australia, Belgium and more
  2. Aug 29, 2016Phase 1 study in Hepatic InsufficiencyBayer · NCT02894385 · 29 enrolled · Germany
  3. Feb 8, 2017Phase 1 study in Biological AvailabilityBayer · NCT03048110 · 15 enrolled · Germany
  4. Jul 26, 2017Phase 1 study in Prostatic NeoplasmsBayer · NCT03237416 · 15 enrolled · Germany
  5. Oct 10, 2018Phase 1 study in Cerebrovascular CirculationBayer · NCT03704519 · 26 enrolled · United Kingdom
  6. Oct 21, 2019Phase 2 study in Prostatic Neoplasms, Castration-ResistantBayer · NCT04157088 · 30 enrolled · United States
  7. Jul 7, 2020Phase 3 study in NeoplasmsBayer · NCT04464226 · 774 enrolled · United States, Argentina, Australia and more
  8. Jan 29, 2021Phase 3 study in Prostatic NeoplasmsBayer · NCT04736199 · 669 enrolled · Australia, Brazil, Canada and more
  9. Sep 17, 2021Phase 2 study in Prostatic NeoplasmsBayer · NCT05059236 · 223 enrolled · United States
  10. Apr 21, 2022Phase 4 study in Prostatic NeoplasmsBayer · NCT05348876 · 50 planned · India
  11. Aug 31, 2022Phase 2 study in Biochemically Recurrent Prostate CancerBayer · NCT05526248 · 28 enrolled · United States
  12. Mar 21, 2023Phase 3 study in Biochemically Recurrent Prostate CancerBayer · NCT05794906 · 985 enrolled · United States, Australia, Austria and more
  13. Feb 12, 2026Phase 2 study in High-risk Localized Prostate CancerBayer · NCT07450599 · 250 planned · China
  14. Nov 5, 2026Primary completion moved from 2027-04-29 to 2027-12-30Date moved laterphase 4 · +8 months · NCT05348876

Ahead

  1. Jul 30, 2027Primary completion: phase 3 study in Biochemically Recurrent Prostate CancerBayer · NCT05794906
  2. Dec 30, 2027Primary completion: phase 4 study in Prostatic NeoplasmsBayer · NCT05348876
  3. Jun 26, 2028Primary completion: phase 3 study in NeoplasmsBayer · NCT04464226
  4. Oct 15, 2028Primary completion: phase 2 study in High-risk Localized Prostate CancerBayer · NCT07450599

TargetBeta

AR →read by rule
“A formulation containing an androgen receptor (AR) antagonist ”NCIt, by rule
“Androgen Receptor antagonist”ChEMBL 37, by rule

Other programs on AR

ProgramCompanyFurthest phaseStudies
enzalutamideruleAstellas Pharmaphase 469
apalutamideruleJohnson & Johnsonphase 431
Clascoteronerulecassiopea-spaphase 419
ostarinerulegtxphase 315
rezvilutamideruleJiangsu HengRui Medicinephase 313
dezandrodegruleBristol-Myers Squibbphase 35
Cyproterone AcetateruleEurofarma Laboratoriosphase 34
Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915Johnson & Johnsonphase 33
HRS-5041Jiangsu HengRui Medicinephase 26
luxdegalutamideNovartisphase 23
luxdegalutamideNovartisphase 22
Androgen Receptor Degrader AZD9750ruleAstraZenecaphase 21

Studies

All 20 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07450599High-risk Localized Prostate Cancer · China2RecruitingBayerOct 15, 2028250
NCT05794906Biochemically Recurrent Prostate Cancer · United States, Australia, Austria and more3Active, not recruitingBayerJul 30, 2027985
NCT05526248Biochemically Recurrent Prostate Cancer · United States2CompletedBayerAug 20, 202428
NCT05348876Prostatic Neoplasms · India4RecruitingBayerDec 30, 202750
NCT05059236Prostatic Neoplasms · United States2CompletedBayerMay 30, 2025223
NCT04736199Prostatic Neoplasms · Australia, Brazil, Canada and more3CompletedBayerJun 7, 2024669
NCT04464226Neoplasms · United States, Argentina, Australia and more3Active, not recruitingBayerJun 26, 2028774
NCT04157088Prostatic Neoplasms, Castration-Resistant · United States2TerminatedBayerJul 8, 202230
NCT03704519Cerebrovascular Circulation · United Kingdom1CompletedBayerOct 1, 201926
NCT03237416Prostatic Neoplasms · Germany1CompletedBayerOct 5, 201715
NCT03048110Biological Availability · Germany1CompletedBayerMay 4, 201715
NCT02894385Hepatic Insufficiency · Germany1CompletedBayerApr 10, 201729
NCT02799602Metastatic Hormone-sensitive Prostate Cancer · United States, Australia, Belgium and more3CompletedBayerOct 25, 20211,306
NCT02671097Healthy Volunteers · Germany1CompletedBayerMay 201630
NCT02418650Healthy · United Kingdom1CompletedOrion Corporation, Orion PharmaMay 201512
NCT02363855Prostatic Neoplasms · Japan1CompletedBayerNov 19, 20159
NCT02200614Prostate Cancer Non-Metastatic · United States, Argentina, Australia and more3CompletedBayerSep 3, 20181,509
NCT01784757Prostatic Neoplasms · Latvia1CompletedOrion Corporation, Orion PharmaAug 201330
NCT01429064Prostatic Neoplasms · United States, Czech Republic, Estonia and more2CompletedOrion Corporation, Orion PharmaNov 201576
NCT01317641Prostatic Neoplasms · United States, Czech Republic, Estonia and more2CompletedOrion Corporation, Orion PharmaJul 2013136

How it is read

Names in the registry

  • “Darolutamide”, 6 entries
  • “Darolutamide (Nubeqa, BAY1841788)”, 5 entries
  • “Darolutamide (BAY1841788, Nubeqa)”, 2 entries
  • “BAY1841788 (ODM-201)”, 2 entries
  • “ODM-201”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.